A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) | MicrobiomeTrials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-29Est. Completion: 2027-12-31
Enrollment target: 48 participants
Locations
The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
Peking University People's Hospital, Beijing, Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Jingzhou Central Hospital, Jinzhou, Hubei, China
Wuxi Second People's Hospital,, Wuxi, Jiangsu, China
The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China
Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China